This strategy was used to isolate a scFv masking unit for the therapeutic antibody 6G11 (BI‐1206), which is currently in clinical trials for the treatment of B‐cell lymphoma to block the inhibitory Fcγ receptor IIB (CD32b). This evidence concerns the gene FCGR2B and B-cell non-Hodgkin lymphoma.